Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO

Assenagon Asset Management S.A. lifted its holdings in Organogenesis (NASDAQ:ORGO) by 69.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,854,942 shares of the company’s stock after purchasing an additional 1,997,038 shares during the quarter. Assenagon Asset Management S.A. owned 3.83% of Organogenesis worth $20,488,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ORGO. First Light Asset Management LLC acquired a new stake in Organogenesis in the 2nd quarter valued at $24,804,000. Vanguard Group Inc. grew its holdings in shares of Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after acquiring an additional 841,618 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Organogenesis by 3.9% in the second quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock valued at $8,862,000 after acquiring an additional 91,118 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in Organogenesis during the first quarter worth about $7,756,000. Finally, Invesco Ltd. boosted its position in Organogenesis by 779.7% during the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock valued at $4,619,000 after purchasing an additional 947,705 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Performance

NASDAQ ORGO opened at $5.60 on Friday. The stock has a market cap of $710.70 million, a PE ratio of -46.67 and a beta of 1.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The firm has a 50-day moving average of $4.88 and a 200-day moving average of $4.51. Organogenesis has a 52-week low of $2.61 and a 52-week high of $7.08.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. On average, sell-side analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a research report on Monday. BTIG Research restated a “buy” rating and set a $9.00 target price on shares of Organogenesis in a report on Monday, December 15th. Finally, Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.00.

Insider Transactions at Organogenesis

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the transaction, the director owned 2,565,591 shares in the company, valued at $13,187,137.74. This represents a 7.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 500,000 shares of company stock valued at $2,620,120. Insiders own 33.00% of the company’s stock.

Organogenesis Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.